{
  "responseHeader":{
    "status":0,
    "QTime":1,
    "params":{
      "q":"(Background: melanoma OR Doc_title: melanoma) AND (Background: tumor cells AND PD-L1 expression AND negative)"}},
  "response":{"numFound":33,"start":0,"docs":[
      {
        "Meeting_name":" Programmed death ligand 1 (PD-L1) expression in paired melanoma tumor samples",
        "Background":"['Background', ' There is limited information on changes in PD-L1 expression levels over time in melanoma.Methods', ' PD-L1 expression was measured in melanoma tumor samples collected at different time points from the same patient using a prototype immunohistochemistry (IHC) assay with the 22C3 antibody. PD-L1 positivity was defined as staining in 1% of cells. The concordance of PD-L1 expression in paired samples was analyzed by treating the IHC proportion score as a continuous variable or classifying staining as positive or negative.Results', ' 48 patients were included. Median age was 65 years (range, 23-85), 73% were male, and 60% had stage I-IIIA disease. All first samples and 85% of second samples were surgical samples. The median interval between sample collection dates was 25.3 months (range, 3.1-203.5). There was no statistically significant correlation of the PD-L1 IHC proportional score between paired samples (Pearson correlation coefficient, 0.13). 40% of patients had an increased proportion score at the second time point, and 10% had a decreased score. The prevalence of PD-L1 positivity was 31% in first samples and 46% in second samples. The concordance rate was 65% (95% CI, 49%-78%) when PD-L1 expression was categorized as positive or negative (Table). The concordance rate was similar in paired samples collected within and beyond 2 years.Conclusion', ' Our preliminary analysis did not suggest a significant correlation of PD-L1 expression in paired melanoma samples collected at different time points. Similar results were observed when samples were categorized as PD-L1 positive or PD-L1 negative. The 35% discordance rate between initial and subsequent tumor samples should be considered if PD-L1 expression is used for selection of enrollment in clinical trials.']",
        "Doc_id":"AACR_2015-4303",
        "Doc_title":" Programmed death ligand 1 (PD-L1) expression in paired melanoma tumor samples",
        "_version_":1606189036576178176},
      {
        "Meeting_name":" The role of SOCS-1 in stimulating melanoma development through growth factor receptors and MAPK pathways",
        "Background":"['Knowledge on the regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now recognized that multiple signaling pathways that affect motility, growth control, invasion, metabolism, cytokine release and the ability to escape the immune response, regulate melanoma development. Silencing of SOCS-1 protein, a negative regulator of Jak/Stat pathway, leads to partial reversion of the tumorigenic phenotype of B16F10-Nex2 melanoma cells. SOCS-1 silencing with shRNAi inhibits in vitro growth by cell cycle regulation with S phase arrest and increased size of cells and nuclei. It also inhibited tumor cell migration and invasion. Down-regulation of SOCS-1 decreased the expression of epidermal growth factor receptor (mainly the phosphorylated-R), Ins-R, and fibroblast growth factor receptors. Based on the results of SOCS-1 silencing, the present work aims at analyzing the expression of proteins relevant to tumor development, searching for signaling pathways related with SOCS-1. A protein microarray analysis of murine melanoma cells silenced for SOCS-1 by shRNAi SOCS-1 lentivirus transduction was undertaken using as controls, cells transduced with the empty vector. Among the 614 differentially expressed genes some cytokine/growth factor receptors were down regulated, e.g. c-kit, met and EphA3. Western blotting of B16 shR-SOCS-1 cell extracts showed a significant decrease in the expression of these receptors, indicating that SOCS-1 positively regulates the MAPK pathways in these cells. We analyzed the main MAPK pathways that were up regulated in melanoma and observed a decrease in the phosphorylation of mediators of ERK1/2 and p38 pathways and of STAT3 (S727). These results demonstrate that SOCS-1 can play an important role in tumor development and progression up regulating a number of growth factor receptors in murine melanoma cells. Interestingly, p-CREB (S133) was up regulated in the SOCS-1-deficient B16F10-Nex2 cells. In vivo experiments showed that using a prophylactic protocol, the subcutaneous immunization of syngeneic mice with B16 shR-SOCS-1 viable cells, rendered a protective effect against subcutaneously grafted and metastatic murine melanoma, with significant reduction in tumor growth and metastates in the lungs. A flow cytometry assay showed decreased expression of PD-L1 at the surface of B16 shR-SOCS-1 cells. This might explain the protective effect of subcutaneous immunization with these cells, rather than with wild-type B16F10-Nex2 cells that overexpress PD-L1, which negatively regulates T-cell immune response. Down regulation of PD-L1 is compatible with inactive ERK. The present results show the important role of SOCS-1 in murine melanoma stimulating cell growth and migration, allowing for the invasive phenotype.']",
        "Doc_id":"AACR_2014-5296",
        "Doc_title":" The role of SOCS-1 in stimulating melanoma development through growth factor receptors and MAPK pathways",
        "_version_":1606189037506265088},
      {
        "Meeting_name":" Up-regulation of PD-L1 in melanoma determines resistance to BRAF and MEK inhibitors, induces a more aggressive phenotype and is partially mediated through post-transcriptional mechanisms involving miR-17-5p",
        "Background":"['Introduction', ' The therapy of metastatic melanoma (MM) was radically changed by the introduction of BRAF inhibitors (BRAFi). Even if highly effective in the short term, patients invariably develop resistance in the long term. For this reason other inhibitors as well as alternative or complementary therapeutic strategies are being tested in these patients. Among the immune checkpoint targets of clinical importance is PD-1, which is expressed by T cells and which binds to the PD-L1 ligand, which may be expressed by melanoma cells. We and others showed that PD-L1 is an independent negative prognostic marker for patients with MM.Methods', ' BRAFi-/MEKi-resistant melanoma cell lines were generated by treating cells with increasing concentrations of BRAFi or MEKi. Resistance, viability and aggressiveness were analyzed by MTT, migration and wound healing assays. Results were confirmed using xenograft models. Resistant cell lines were compared using RNAseq to identify enriched genetic pathways involved in the resistance. Luciferase reporter assay analysis was used to study the direct interactions between the PD-L1 and miR-17-5p.Results', ' By comparing responses to BRAFi in PD-L1+ and PD-L1- variants of the A375 cell line, we found that PD-L1 expression conferred resistance to BRAFi or MEKi. Conversely, silencing of the molecule restored sensitivity to these drugs. Resistant melanoma cell lines acquired PD-L1 expression and were characterized by a specific genetic profile, with the modulation of genes controlling cell movement and immune responses. Consistently, these cells showed a more aggressive behavior both in vitro and in xenograft models. PD-L1 silencing in resistant cells decreased invasive properties and restored expression of HLA-II molecules.PD-L1 up-regulation was only partly dependent on the paradoxical activation of the MAPK pathway, which characterized resistant cells. In addition, we found that resistance to BRAFi and MEKi down-modulated miR-17-5p, which showed an inverse correlation with PD-L1. Transfection of miR-17-5p into BRAFi-resistant cell lines induced the down-modulation of PD-L1, reduced the aggressive behavior of the cells and partially restored sensitivity to BRAFi. Finally, in the plasma of patients with MM, miR-17-5p was inversely correlated with expression of PD-L1 in the tumor tissue.Conclusions', ' These data demonstrate a direct link between expression of PD-L1 and resistance to BRAFi, as well as to a more aggressive behavior of melanoma cells. Furthermore, we define a novel post-transcriptional circuit responsible for PD-L1 up-regulation, based on a direct interaction between miR-17-5p and PD-L1 mRNA. Lastly, miR-17-5p plasmatic levels show an inverse correlation with PD-L1 expression by tumor cells, suggesting that they may be useful in monitoring disease outcome and drug sensitivity.']",
        "Doc_id":"AACR_2016-241",
        "Doc_title":" Up-regulation of PD-L1 in melanoma determines resistance to BRAF and MEK inhibitors, induces a more aggressive phenotype and is partially mediated through post-transcriptional mechanisms involving miR-17-5p",
        "_version_":1606188997672960000},
      {
        "Meeting_name":" Development of an immunohistochemistry assay for PD-L1 for using the 22C3 antibody in melanoma.",
        "Background":"['Background', ' The expression of PD-L1 has been reported in a number of human malignancies. Studies showed the correlation of PD-L1 expression in tumor or inflammatory cells, with clinical outcomes, which indicate that PD-L1 may be a predictive biomarker. PD-L1 expression on tumors contributes to tumor escape from immune surveillance. Here we describe the development of a highly reproducible and robust immunohistochemistry (IHC) assay for melanoma. Methods', ' IHC staining procedure was performed using the Dako Autostainer Link 48 platform (Dako AS480) and an automated staining protocol validated for the PD-L1 IHC 22C3 pharmDx assay. Deparaffinization, rehydration and target retrieval was performed in the PT Link (Dako PT100) using a 3-in-1 procedure. The enzymatic conversion of the subsequently added 3,3-diaminobenzidine tetrahydrochloride (DAB) chromogen followed by DAB enhancer resulted in precipitation of a visible reaction product at the site of antigen. The specimens were then counterstained with Hematoxylin and coverslipped. Results were interpreted using a light microscope. Results', ' The in-house analytical validation consisted of inter-instrument, -operator, -day, and lot, and intra-day and -run variations. Robustness studies included differences in target retrieval time, temperature and pH. Negative, positive and overall agreements met the acceptance criteria for all these studies. Interpretation included PD-L1 expression on tumor and immune cells. Conclusions', ' Our studies demonstrate that the Dako PD-L1 IHC 22C3 assay is a sensitive, specific, precise, and robust assay, which can reliably identify patients who express PD-L1 as a biomarker across multiple tumor types. Clinical trial information', ' NCT01295827']",
        "Doc_id":"ASCO_170995-176",
        "Doc_title":" Development of an immunohistochemistry assay for PD-L1 for using the 22C3 antibody in melanoma.",
        "_version_":1606189004879822848},
      {
        "Meeting_name":" Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients",
        "Background":"['While PD-1/L1 axis-targeted therapies have shown promising clinical responses, their use in combination therapies is associated with both benefits and safety concerns. Response rates for single-agent anti-PD-1 therapies are significantly higher in biomarker positive patients, therefore there is a need to utilize predictive diagnostics to enhance benefit-risk profiles and guide treatment decisions. To address this, we developed a novel quantitative multiplexed immunohistochemistry assay that provides objective quantitation of PD-L1 positive cells, but more importantly assesses interactions with immune cells (PD-1+ or CD8+) in formalin-fixed paraffin embedded (FFPE) clinical specimens. The clinical validity of this assay was verified in a small series of melanoma patients treated with anti-PD1 targeted therapies/agents.FFPE melanoma tissues from patients who received anti-PD-1 therapy were fluorescently stained with a combination of anti-PD-1, PD-L1, and S100 antibodies plus DAPI or a combination of anti-CD8, PD-L1, and S100 antibodies plus DAPI. Each slide was then imaged on Vectra platform and the frequencies of biomarker positive cells (PD-L1, PD-1, and CD8) and their interaction scores were objectively evaluated using proprietary Automated Quantitative Analysis (AQUA) algorithms. Analytical sensitivity, precision, and accuracy were established using standardized PD-L1 and PD-1 tissue control arrays composed of cell lines and lymphoid organs, while range of biomarker expression was verified on archived melanoma clinical specimens (n = 30), including samples taken from melanoma patients prior to anti-PD-1 therapies (n = 21).Frequencies of PD-L1 positive cells could be accurately quantified within 1% to 100% range in predefined control cell line mixtures. PD-L1 and PD-1 measurements were highly reproducible (R2 = 0.98 and 0.97, respectively). A broad range of PD-L1 and PD-1 expression and interaction scores were observed in archival clinical specimens (n = 53). In a cohort of 21 advanced melanoma patients treated with nivolumab (n = 5) or pembrolizumab (n = 16), the PD-1/L1 interaction score was found to reliably distinguish responders from non-responders (p = 0.03) while PD-L1 alone (p = 0.15) or CD-8 alone (p = 0.23) did not. Additionally, patients exhibiting higher PD-1/L1 interaction scores had superior response rates (78% vs. 17%, p = 0.03). Responders experienced significantly longer median progression-free survival (177 vs. 85 days, p = 0.014), and fewer deaths (22% vs 58%) compared with patients having lower PD-1/L1 interaction scores.In terms of diagnostic utility, the PD-1/L1 multiplex test showed superior predictive power (78% Positive Predictive Value, 83% Negative Predictive Value) compared with PD-L1 expression alone. Additional studies are underway to fully establish diagnostic utility and aid in treatment guidance.']",
        "Doc_id":"AACR_2016-853",
        "Doc_title":" Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients",
        "_version_":1606188980570685440},
      {
        "Meeting_name":" Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma.",
        "Background":"['Background', ' PD-L1 expression on tumors contributes to tumor escape from immune surveillance. In order to determine whether PD-L1 might be useful to identify those patients (pts) with melanoma most likely to respond to pembro, an IHC assay was developed for use in pembro clinical trials. Methods', ' The PD-L1 IHC assay was performed on the Dako platform using the 22C3 antiPD-L1 antibody. In contrast to development of this assay for nonsmall cell lung cancer (NSCLC), scoring included mononuclear inflammatory cells intercalated and contiguous with tumor cells. A 6-point score was defined as', ' IHC0 (no staining), IHC1 ( < 1% staining), IHC2 (1%-9%), IHC3 (10%-32%), IHC4 (33%-65%), and IHC5 (66%-100% staining). The presence of distinct patterns (interface or dendritic) was also noted. Using data from 135 patients treated with pembro in KEYNOTE-001 (NCT01295827), 88 samples were evaluable for PD-L1 IHC and had central RECIST response data for use in a training set. Samples with obscuring melanin or insufficient tumor were not evaluable. Receiver operating characteristic (ROC) analysis was performed. Results', ' The ROC curve was somewhat flat. A score of IHC2 (1% staining) was chosen to optimize the true positive rate (clinical sensitivity) and negative predictive value. A 2  2 table is shown below comparing responders and nonresponders at the IHC2 cutoff. Assay performance could not be improved by incorporating the interface or dendritic patterns. Conclusions', ' PD-L1 is not a strong enough predictor of response to be used as a companion diagnostic for pembrolizumab monotherapy. However, PD-L1 testing could help guide treatment decisions in melanoma in clinical situations in which several treatment options are available. Although 66% of samples in this cohort were PD-L1positive, higher prevalence (81%) was observed in the previously reported data from KEYNOTE-006 (NCT01866319), a randomized, controlled clinical trial for pembro in melanoma. Clinical trial information', ' NCT01295827RespondersNon-RespondersPD-L1 IHC Score = 0,1624PD-L1 IHC Score = 2, 3, 4, 52434']",
        "Doc_id":"ASCO_167205-176",
        "Doc_title":" Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma.",
        "_version_":1606189036249022465},
      {
        "Meeting_name":" Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.",
        "Background":"['Background', '    PD-1 activation by ligands (PD-L1 and PD-L2) inhibits T-cell activation and facilitates cancer progression. Trials exploring interruption of PD-1/PD-L1 signaling showed benefit in several cancer types, but the complexity of PD-L1 expression and patterns of PD-1 tumor infiltrating lymphocytes (TIL) make development of the predictive biomarker challenging. We analyzed distribution of PD-1+ lymphocytes and PD-L1 expressing tumor cells in common cancer types and their association with other cancer characteristics.  Methods', '    339 carcinomas  (lung, breast, prostate, colon, ovary, endometrium, kidney, liver, bladder, pancreas) and 24 melanomas were profiled (Caris Life Sciences) using immunohistochemistry, in-situ hybridization and next generation sequencing (Illumina TruSeq panel).  Results', '  PD-1+ lymphocytes are consistently identified in reactive, peri-tumoral lymphoid follicles, but intra-tumoral PD-1+ lymphocytes in direct cell-to-cell contact with cancer cells were less common (e.g. 50% of breast cancers, 58% melanomas and 75% of NSCLC). PD-L1 was consistently detected in tumor microenvironment (endothelium, macrophages, myofibroblasts), but specific cancer cells expression of PD-L1 was less common (e.g. 43% BrCA, 52% NSCLC, 21% sporadic CRC), except in melanomas which were PD-L1+ in 92% of cases. Intra-tumoral PD-1+ TILs and PD-L1+ cancer cells were co-present in 58% melanomas, 44% NSCLC, 28% breast carcinomas and 8% CRC. Triple-negative breast cancers (TNBC) were frequently PD-L1 positive (59% all TNBC and 100% in metaplastic TNBC). In NSCLC, PD-1+/PD-L1+ tumors were mostly seen in the absence of targetable genetic abnormality (i.e. EGFR, ALK and ROS1 negative).  Conclusions', '  The study provides useful guidance for evaluation of PD-1 and PD-L1 as potential biomarkers for clinical trials as well as their frequency distribution in different types of malignancies. Not all patients respond to immunotherapy and intratumoral PD-1+ TILs and cancer specific PD-L1 expression may be required for the potential benefit to immune checkpoint inhibition therapy.']",
        "Doc_id":"ASCO_134456-144",
        "Doc_title":" Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.",
        "_version_":1606189016584028160},
      {
        "Meeting_name":" Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.",
        "Background":"['Background', '  Nivolumab and ipilimumab are fully human monoclonal antibodies that block the immune checkpoint receptors PD-1 and CTLA-4, respectively. In a multi-cohort, phase I study of nivolumab/ipilimumab combination therapy in melanoma patients (pts), objective response rates up to 47% were observed (NCT01024231). Putative predictive biomarkers from peripheral blood (PB) or tumor, including tumor PD-L1 expression, absolute lymphocyte count (ALC) and PB myeloid derived suppressor cells (MDSC) were evaluated. Pharmacodynamic changes in activated and effector T cells were also assessed.   Methods', '  Tumor PD-L1 membrane expression was assessed in archival FFPE specimens by immunohistochemistry (28-8 PD-L1 antibody). ALC was measured in serial PB samples; changes in the percentage, number and phenotype of activated CD4+ and CD8+T cells and MDSC were characterized by flow cytometry.   Results', '  PD-L1 expression was seen in 37% (10/27) of pts, using a cut-off of 5% tumor cell membrane staining. Objective responses (OR) were seen in pts with both PD-L1 negative (8/17) and PD-L1 positive (4/10) tumors. Relative to baseline, a rise in ALC was not detected, but phenotypic changes in PB T-cell subsets, including increases in the percentage of CD4 and CD8 expressing HLA-DR, ICOS and/or Ki67 were seen with combination therapy. Low ALC (<1.0 at wk 6-7) did not preclude OR as 3 of 12 pts with low ALC responded. Of pts evaluated, OR with 80% reduction in tumor burden at 12 wk were seen in pts with a low frequency of pretreatment PB MDSC (3/7) but no OR were seen in pts with high MDSC (0/6).   Conclusions', '  In this small subset of pts,OR were seen independent of PD-L1 or ALC status in contrast to prior observations with nivolumab or ipilimumab, respectively. Thus, the immune response generated by combination therapy may have unique features compared to either monotherapy. The relationship between frequency of PB MDSC and reduction in tumor burden will be further explored. Further efforts in this study and in future phase III randomized studies will investigate these and other phenotypic changes in immune cell populations and their relationship to patterns of clinical activity. Clinical trial information', ' NCT01024231.']",
        "Doc_id":"ASCO_113277-132",
        "Doc_title":" Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.",
        "_version_":1606188994368897024},
      {
        "Meeting_name":" Association of soluble PD-L1 (sPD-L1) with decreased survival in metastatic melanoma.",
        "Background":"['Background', ' Membrane expression of PD-L1 on tumor cells is associated with poor survival in patients with advanced malignancies including metastatic melanoma (MM). In addition, tumor-associated PD-L1 has been proposed as a predictor of response to anti-PD-1 therapy, although responses are observed in some cases of PD-L1 negative MM. We hypothesize that tumor-derived PD-L1 has additional systemic effects through the release of biologically active soluble forms of PD-L1 (sPD-L1) into the circulation, which further impedes the anti-tumor immune response and contributes to poor clinical outcomes in MM. Methods', ' We developed a sPD-L1 ELISA and biochemically confirmed the identity of the detected protein. We measured the levels of sPD-L1 in 276 patients with MM enrolled on 3 clinical trials who had stored pre-treatment plasma samples and 37 healthy volunteers (HV) undergoing blood donation at Mayo Clinic. We also measured sPD-L1 in baseline samples from 38 MM patients treated with anti-PD1 (pembrolizumab) 2 mg/kg every 3 weeks. ROC analysis was used to compute sPD-L1 concentration cut-off value and Wald test was used to asses the difference of overall survival (OS) in patients with low versus high sPD-L1 concentration. Results', ' We found that sPD-L1 levels were significantly elevated in MM patients compared with HV (p=0.0011). Mean sPD-L1 level in MM was 1.73 ng/mL (range', ' 0.13-18.29) compared with 0.77 ng/mL (range', ' 0.116.02) for HV. Patients with higher levels (>0.293 ng/mL) had a median OS of 11.3 months compared to 14.8 months for patients with sPD-L1 level  0.293 ng/mL (p=0.040). Similarly to tumor-related PD-L1 findings, patients who had clinical benefit (OR/PR/SD) after 4 cycles of anti-PD1 had higher sPD-L1 levels at baseline (2.1 vs. 1.1 ng/mL). Conclusions', ' To our knowledge, our study is the first to report a correlation of sPD-L1 with MM patient outcome, although a larger study is needed to establish the utility of sPD-L1 as an independent prognostic and possibly predictive biomarker.']",
        "Doc_id":"ASCO_178659-194",
        "Doc_title":" Association of soluble PD-L1 (sPD-L1) with decreased survival in metastatic melanoma.",
        "_version_":1606189018204078080},
      {
        "Meeting_name":" Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer.",
        "Background":"['Background', '  Immunotherapy with checkpoint blockade has shown encouraging activity in squamous cell carcinomas including a case report in tongue cancer (Herbst 2013). PD-L1 expression is common in HNC (Lyford-Pike 2013). In melanoma a T cell-infiltrated phenotype is common and correlates with immune inhibitory pathways. We interrogated the immune microenvironment in a large cohort of HNC in order to identify molecular correlates of an inflamed tumor microenvironment that may predict benefit from checkpoint blockade.  Methods', '  We evaluated the presence of a T cell-inflamed tumor microenvironment in a cohort of 134 (Chicago HNC Genomics (CHGC)) and 424 TCGA HNC samples using a melanoma expression signature (Harlin/Gajewksi 2009). We evaluated multiple immune-related markers by IHC in a subset of CHGC tumors including CD8 tumor infiltrating lymphocytes (TIL)(N=73) and PD-L1 (N=55). Results were correlated with genetic and clinical information.  Results', '  47% of CHGC and 33% of TCGA tumors showed a T cell-inflamed phenotype (TCIP) similar to melanoma based on a gene expression signature (Harlin 2009).  75% of HPV(+) tumors showed a TCIP compared to 23% of HPV(-) tumors in both cohorts. Mesenchymal subtype (Keck 2014) strongly correlated with TCIP (p<2.2x1016), and 90% of mesenchymal tumors showed TCIP including roughly equal numbers of HPV(+) and HPV(-) tumors in both cohorts. Basal and HPV-negative classical HNC tumors were TCIP negative. Based on IHC, 38% of CHCG tumors showed PD-L1 expression and 64% showed CD8+ TILs, both correlating with TCIP. Additional checkpoint molecules were universally co-expressed in the same TCIP tumors including CTLA4, LAG3, PDL-2, and IDO. Molecular processes enriched in non-TCIP tumors included EGFR/erbB signaling (p=0.09) characteristic of basal HNC, while multiple T-cell related signatures and the JAK/STAT pathway (p<0.05) characteristic of mesenchymal HNC were enriched in the TCIP tumors.  Conclusions', '  33-47% of HNC show a T cell-inflamed phenotype similar to melanoma. PD-L1 expression and TIL presence is common and strongly correlated with mesenchymal HNC in both HPV(+) and HPV(-) HNC and may benefit from immunotherapy.']",
        "Doc_id":"ASCO_130011-144",
        "Doc_title":" Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer.",
        "_version_":1606188999581368320},
      {
        "Meeting_name":" mDX400, the murine analog against the anti-PD1 antibody MK-347 is active in immunocompetent, autochthonous murine models of melanoma and breast cancer",
        "Background":"[\"Although effective therapies exist for BRAF-mutant metastatic melanomas (MM) and ER+/PR+/HER2+ breast cancers, fewer options are available for the more aggressive triple negative breast cancers (TNBC) and Ras-mutant MM. Immune infiltration is frequently observed in patient subsets with MM or TNBC. An anti-tumor host immune response may be restrained by the expression of immune checkpoint proteins, such as the programmed death 1 (PD1) protein. We evaluated mDX400, a murine version of the anti-PD-1 antibody MK-3475 that is currently in human clinical trials, in genetically engineered murine models (GEMMs) of melanoma and breast cancer (BC). PD1 antibody was used alone and in combination. Models studied were for basal-like, TNBC (C3TAg), Claudin-Low breast cancer p53null, luminal BC (MMTV-Her2/Neu), RAS-driven melanoma (Tyr-H-Ras and null for Ink4a/Arf (TRIA)) and BRaf-mutant, Pten-deficient melanoma (BRaf/Pten). Mice were housed, treated, and evaluated in the UNC Lineberger Comprehensive Cancer Center Mouse Phase I Unit (MP1U). mDX400 and isotype antibody (10mg/kg IP qw) were supplied by Merck & Co., Inc. Murine cohorts were assessed weekly and therapeutic intervention began once tumors reached 40-64mm3. TNBC models were treated with Carboplatin (C, 50mg/kg IP qwk) in combination with mDX400. mDX400 was administered as a single agent in Melanoma GEMMs. Endpoints were maximal response at 21 days and median overall survival (OS). In the C3TAg BC model, mDX400 did not exhibit single-agent activity, but substantial synergy was observed in combination with C [partial response (PR) or CR in 12 of 15 vs. 0 of 19 in non-treated animals, Fisher's exact p=0.006 or vs. C alone 5 of 13 animals, p=0.05] and prolonged OS (41 vs. 28 days in NT, log-rank p=0.006 or C only 28 days, p=0.006) in the C3TAg model. Treatment with single-agent mDX400 induced a marked response in the RAS-driven TRIA melanoma model that is resistant to multiple systemic treatments. mDX400-treated TRIA mice enjoyed an almost tripling of OS [median 56 vs. 21 days, p=0.006]. BRaf/Pten melanomas did not respond to mDX400. Likewise mDX400 plus C provided no benefit to the p53null or MMTV-Her2/Neu BC GEMMs vs. C alone. Our data show differential response of PD-1 antibody therapies to various melanoma and BC models, the latter in combination with C. The responsiveness of a RAS-driven melanoma model to mDX400 is consistent with earlier reports about the clinical benefit of patients with NRAS-mutant melanoma to Ipilimumab, and the lack of PD-L1 expression and immune infiltrates of PTEN-deficient melanomas. At the meeting we will report expression of PD-L1 and other immune checkpoint proteins by cancer cells. The basis whereby carboplatin potentiates the activity of anti-PD1 in TNBC is an area of ongoing study.\"]",
        "Doc_id":"AACR_2014-5024",
        "Doc_title":" mDX400, the murine analog against the anti-PD1 antibody MK-347 is active in immunocompetent, autochthonous murine models of melanoma and breast cancer",
        "_version_":1606188986118701056},
      {
        "Meeting_name":" Optimization of an assay for the detection of PD-L1 by immunohistochemistry in formalin-fixed, paraffin-embedded human tissue and cell lines",
        "Background":"['Programmed Death-1 (PD-1) is a member of the CD28 family of receptors and plays a role in cellular immune response. It is expressed on activated T-cells and B-cells and binds to two ligands, Programmed Death Ligand 1 (PD-L1) and Programmed Death Ligand 2 (PD-L2). PD-1 negatively regulates T-cell functions through interactions with its primary ligand PD-L1, which is variably expressed by a variety of tumors, including melanoma, glioblastoma, and carcinomas of the lung, breast, colon, ovary, and renal cells. Many tumor cells express PD-L1 and as a result, the interaction between PD-1 and PD-L1 has been demonstrated to be an important target for therapeutic intervention. Anti-PD-1 therapeutics such as pembrolizumab and nivolumab have demonstrated clinical activity in melanoma, non-small cell lung cancer and other types of cancer. The purpose of this study was to investigate 7 commercially available anti-PD-L1 antibodies in human tissue and cell lines. Antibodies included 1 mouse monoclonal (clone 29E.2a3), 2 rabbit monoclonals (EPR1161(2) and E1L3N), 3 rabbit polyclonals, and 1 goat polyclonal from 6 manufacturers. An initial screen in human tonsil was performed to ensure appropriate sensitivity and specificity in staining of the crypt epithelium. Only 2 antibodies yielded staining that matched the expected specificity and were selected for further evaluation', ' rabbit clone EPR1161(2) from Abcam and rabbit clone E1L3N from Cell Signaling. Antibody specificity was evaluated in a positive cell line (MDA-MB-231) and negative cell line (MCF-7). Both antibodies demonstrated appropriate specificity in these cell lines. Antibody sensitivity was evaluated in a variety of human tumor tissues provided by Mosaic Laboratories tissue bank. PD-L1 localization was expected to be membranous and cytoplasmic in tonsil crypt epithelium, inflammatory cells and tumor cells. Immunohistochemistry with both antibodies demonstrated staining in tumor cells, lymphocytes and macrophages. Immunohistochemistry with clone E1L3N often demonstrated stronger staining in a greater percentage of cancer cells than EPR1161(2). Of interest, clone E1L3N demonstrated specific staining of some peripheral nerve fibers that was not observed with clone EPR1161(2). In conclusion, 2 commercially available antibodies, rabbit clone EPR1161(2) from Abcam and rabbit clone E1L3N from Cell Signaling are appropriate for immunohistochemistry, of which rabbit clone E1L3N demonstrates greater sensitivity in tumor tissue.']",
        "Doc_id":"AACR_2015-3396",
        "Doc_title":" Optimization of an assay for the detection of PD-L1 by immunohistochemistry in formalin-fixed, paraffin-embedded human tissue and cell lines",
        "_version_":1606188993016233984},
      {
        "Meeting_name":" Correlation between PD-L1 expression and PD-1 immune checkpoint blockade",
        "Background":"['Background', ' Overexpression of PD-L1 is associated with better clinical responses to PD-1/PD-L1 blockade in melanoma, but the utility of PD-L1 immunostaining as a predictive biomarker for anti-PD-1 treatment remains unclear. Methods', ' We retrospectively assessed 18 patients with metastatic melanoma (10 acral, 8 mucosal primary) who had received anti-PD-1 treatment to evaluate the association between PD-L1 immunostaining status and the efficacy of anti-PD-1 treatment between January and December 2015 at single tertiary center in Korea. Immunohistochemical PD-L1 expression was evaluated with cutoff values of 1% or 5% of immune cells in a tissue section. The primary endpoint was progression free survival (PFS) and secondary endpoints were overall response rate (ORR), disease control rate (DCR), and Safety. Results', ' In the positive group with 1% cutoff, ORR was 20% (2/10) and DCR was 80%; for patients with negative immunostaining, ORR was 12.5% (1/8) and DCR of 37.5%, respectively. With 1% cutoff value, the median PFS was 6.2 months in positive group and 1.6 months in negative group (p = 0.137). In the positive group with 5% cutoff value, ORR was 33.3% (2/6) and DCR was 83.3%; for patients with negative immunostaining, ORR was 8.3% (1/12) and DCR was 50%. With 5% cutoff value, the median PFS was 6.8 months in positive group and 1.9 months in negative group (p= 0.149). One patient with positivity for anti-PD-L1 immunostaining (  5%) and three patients with negativity for anti-PD-L1 immunostaining ( < 1%) continued anti-PD-1 treatment beyond RECIST-defined disease progression. These four patients experienced stable disease with immunotherapy for more than 5 months since the date of documented initial disease progression. Anti-PD-1 treatment was very well tolerated without serious adverse events of grade 3 or 4 in all patients. Conclusions', ' Within the limitation of a retrospective study, immunohistochemical PD-L1 expression was correlated with better clinical outcomes of anti-PD-1 treatment, but cannot be considered a definitive biomarker for the response to PD-1 checkpoint blockade.']",
        "Doc_id":"ASCO_169981-176",
        "Doc_title":" Correlation between PD-L1 expression and PD-1 immune checkpoint blockade",
        "_version_":1606189005021380608},
      {
        "Meeting_name":" Identification of additional cancers likely to respond to anti-PD-1 therapy (pembrolizumab)",
        "Background":"['Increased PD-L1 expression has been associated with clinical activity of anti-PD-1/PD-L1 therapies in both melanoma and non-small cell lung cancer (NSCLC). Our objective was to identify other cancers that show increased PD-L1 expression in order to target them for treatment with the PD-1 inhibitor pembrolizumab (MK-3475). A collaboration between Merck and the Moffitt Cancer Center was previously established to build a molecular profiling database of >16,000 primary and >3000 metastatic tumors representing 25 different cancers. All tumor samples were profiled on a standardized platform (Affymetrix-Merck Custom GeneChip). For each profiled sample, the PD-L1 cutpoint determined for positivity was defined as the Affymetrix pan-cancer 75th percentile of PD-L1 probes mean. This cutpoint was projected for each specific tumor type and percentages of tumors with PD-L1 above the cutpoint were determined. Cancer indications were rank ordered from highest to lowest percentage of PD-L1 positivity. The analysis identified NSCLC (42% PD-L1+) and melanoma (41% PD-L1+) among the top indications for which single-agent clinical activity of anti-PD1/PD-L1 therapies has been reported. At the bottom of the rankings were prostate cancer (14% PD-L1+) and pancreatic cancer (4% PD-L1+), indications for which limited clinical activity had been reported. This observation confirmed that ranking tumor types by PD-L1 expression across the profiling database could be used to identify other cancers that may respond to anti-PD-1 therapy. Of interest were the tumor types with high PD-L1 expression for which no clinical studies evaluating an anti-PD-1/PD-L1 agent had been initiated. Among the indications with high PD-L1 expression were head and neck (59% PD-L1+), urothelial (42% PD-L1+), and triple-negative (TN) breast (29% PD-L1+) cancer; these indications were chosen for evaluation with pembrolizumab in the KEYNOTE-012 study. By accessing cohorts of Asian patients with lung, liver, and gastric cancer and use of similar gene expression microarray profiling, we were able to extrapolate the PD-L1 rankings for these cancers; this resulted in the addition of gastric cancer to KEYNOTE-012. Recently, clinical results from KEYNOTE-012 have shown strong clinical activity for pembrolizumab in all 4 selected indications', ' head and neck, 20% ORR; urothelial, 21% ORR; TN breast, 18% ORR; and gastric, 31% ORR. The strategy of using a tumor profiling gene expression database for evaluation of PD-L1 expression enabled rapid expansion of pembrolizumab development into indications for which the likelihood of demonstrating clinical activity was high. In turn, this should help accelerate the approval of pembrolizumab for additional indications and, ultimately, provide help to patients suffering from cancer.']",
        "Doc_id":"AACR_2015-256",
        "Doc_title":" Identification of additional cancers likely to respond to anti-PD-1 therapy (pembrolizumab)",
        "_version_":1606188984499699712},
      {
        "Meeting_name":" PD-L1 expression in paired non-small cell lung cancer tumor samples",
        "Background":"['Background There is limited information on changes over time in programmed death ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC).Methods PD-L1 expression was assessed in paired tumor samples collected at different time points from the same patient using a prototype immunohistochemistry (IHC) assay with the 22C3 antibody. PD-L1 strong and weak positivity were defined to be traceable to the 1% and 50% cutoffs used in the clinical trial version of the assay. Concordance of PD-L1 expression between samples was analyzed by treating the IHC proportional score as a continuous and categorical variable.Results 90 patients were included (73 from Korea, 17 from Denmark). 75% were male, 37% had squamous cell carcinoma, and 83% had stage I-IIIA disease. 97% of first samples and 53% of second samples were from lung. 89% and 63%, respectively, were surgical samples, with a median interval of 20.9 months (range, 0.1-94.0) between collection dates; 91% of paired samples were collected >3 months apart. A significant correlation of the PD-L1 IHC proportional score was observed for the paired samples (Pearson correlation coefficient, 0.62; P < 0.001). At the second time point, scores were identical in 39% of paired samples, higher in 32%, and lower in 29%. Of note, 12% of PD-L1-negative cases became positive and 20% of PD-L1-positive cases become negative at the second time point. The concordance rate was 56% (95% CI, 46%-67%) when PD-L1 expression was categorized as strong or weak positive or negative (Table).Conclusion Although a significant correlation of the PD-L1 IHC proportional score was observed, this preliminary analysis suggested a discordance rate of 44% between initial and subsequent NSCLC tumor samples when patients were categorized by PD-L1 expression level. Similar results were observed when analyzing paired melanoma samples. This discordance should be considered if PD-L1 expression is used for selection of enrollment in clinical trials.Table. Concordance of PD-L1 Expression in Paired NSCLC Samples (N = 90)']",
        "Doc_id":"AACR_2015-570",
        "Doc_title":" PD-L1 expression in paired non-small cell lung cancer tumor samples",
        "_version_":1606189009729486848},
      {
        "Meeting_name":" The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers",
        "Background":"['Background', ' Immunotherapy based on anti-PD-1 (Programmed death 1)/PD-L1 (PD-1 Ligand 1) antibodies have achieved significant successes from bench to clinic. In this study, we systematically evaluate the overall efficacy and safety of current anti-PD-1/PD-L1 antibodies for treatment of patients with advanced or refractory cancer. Methods', ' Clinical trials reporting response or safety of anti-PD-1/PD-L1 antibodies for advanced or refractory cancer patients published were searched in PubMed and EMBASE database. Meta-analyses using random effects models were used to calculate the overall estimate. Results', ' Fifty-one trials including 6,800 patients were included. The overall response rates for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) were 29% (95% CI', ' 1.53-2.41), 21% (95% CI', ' 17%-25%) and 21% (95% CI', ' 16%-27%) respectively. While the overall adverse effects rate for melanoma, NSCLC, RCC were 16% (95% CI', ' 6%-28%), 11% (95% CI', ' 8%-14%) and 20% (95% CI', ' 11%-32%) respectively. Tumor PD-L1 expression and patient smoking status might serve as biomarkers to predict response of anti-PD-1/PD-L1 antibody treatment. Compared to tumors with negative PD-L1 expression, tumors with positive PD-L1 expression had a significantly higher clinical response rate (41.4% versus 26.5%) with RR = 1.92 (95% CI', ' 1.53-2.41, P< 0.001). Smoker patients also showed a significantly higher response rate (33.7%) than patients who never smoked (4.2%) with RR = 6.02 (95% CI', ' 1.22-29.75, P= 0.028). Nivolumab and Pembrolizumab were associated with significantly increased response rate (RR = 2.89, 95% CI', ' 2.46-3.40, P< 0.001), reduced death risk (HR = 0.53; 95% CI', ' 0.48-0.57; P< 0.001), and decreased adverse effect rate (RR = 0.49, 95% CI', ' 0.30-0.80, P= 0.004) compared with other therapies. Conclusions', ' Anti-PD-1/PD-L1 antibodies have high response rates and low adverse effect rates for advanced or refractory cancers. PD-L1 expression was associated with better clinical response of anti-PD-1/PD-L1 antibody based immunotherapy.']",
        "Doc_id":"ASCO_185120-199",
        "Doc_title":" The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers",
        "_version_":1606188993178763264},
      {
        "Meeting_name":" A cell based bioluminescent reporter assay for rapid measuring function of PD-1 or PD-L1 therapeutic antibodies",
        "Background":"['Programmed death-1(PD-1) and its ligand (PD-L1) are important immunotherapy targets for cancer. PD-1 serves as a negative costimulatory receptor on various cell types, including T and B cells as well as myeloid-derived cells. Its ligand PD-L1 (B7-H1) is not expressed by normal epithelial tissues, but it is aberrantly expressed on a wide array of human cancers including melanoma, non-small cell lung carcinoma, breast cancer, pancreatic cancer, etc. Engagement of PD-1 by its ligands PD-L1 expressed on tumor cells associated with poorer prognosis by disabling the host antitumor response. The most recent investigational anti-PD-1 immunotherapy drugs such as nivolumab from BMS and lambrolizumab (MK-3475) from Merck have all demonstrated significant overall survival rate in patients with advanced melanoma.Here we developed a cell based bioluminescent reporter assay that can be used for rapid quantifying function of PD-1 or PD-L1 therapeutic antibodies as measured by activation of NFAT signaling pathway. For this, Jurkat T-cell line stably expressing NFAT-luciferase reporter and human PD-1 was generated. Raji stably expressing human PD-L1 was generated as antigen presenting cells (APC). by co-cultivating the two cell lines in the present of CD3 and IgG, Raji cells fully activate Jurkat NFAT pathway via CD28 binding to CD80 (B7-1) and CD86 (B7-2) endogenously expressed on Raji cells. PD-1 signaling in Jurkat cells following engagement of PD-L1 ectopically expressed on Raji cells inhibits T cell function, and results in NFAT pathway inhibition. Blockade of PD-L1 using anti-PD-L1 mAb reversed NFAT pathway activation.']",
        "Doc_id":"AACR_2014-2555",
        "Doc_title":" A cell based bioluminescent reporter assay for rapid measuring function of PD-1 or PD-L1 therapeutic antibodies",
        "_version_":1606189013131067392},
      {
        "Meeting_name":" PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.",
        "Background":"['Background', ' The phase 3 COMBI-v study (NCT01597908) showed that D+T significantly improved outcomes vs vemurafenib inpts with BRAFV600E/Kmutant MM. Checkpoint inhibitors also provide clinical benefit in some pts with MM. To date, characterization of markers associated with response to antiPD-1 therapy has identified positive associations with PD-L1 expression and immune cell infiltration. Here we describe expression of PD-L1 and the T-cell marker CD8 in tumor samples from pts randomized to receive D+T in COMBI-v and associations with clinical outcomes. Methods', ' Biopsies from 74 of 352 D+T pts (21%) in COMBI-v were assessed for expression of PD-L1 (PD-L1 IHC 22C3 pharmDx assay; Dako) and CD8 (anti-CD8 antibody, clone C8/144B; Dako). PD-L1 positivity was determined as a percentage of stained tumor cells and MEL score (staining on both tumor and mononuclear inflammatory cells; 0 or 1 [negative]', ' < 1% staining; 2-5 [positive]', '  1% staining; Daud et al. J Clin Oncol. 2016). Results', ' Of 74 pts analyzed, 54 (73%) had PD-L1positive tumors, and the largest MEL score subgroup was 2 (45%). A significant association (P< .0001) was observed between PD-L1 and CD8 expression. Overall response rate, tumor shrinkage, progression-free survival, overall survival (OS), and duration of response with D+T were not associated with PD-L1 (MEL score of  2) or CD8 positivity. However, a significant association (P = .04) with improved OS was observed in tumors with high PD-L1 expression ( 20% of cells PD-L1 positive), and a trend (P = .06) was seen in pts with a MEL score of  3. Among PD-L1negative pts, improved OS was seen in those with high CD8 positivity (P = .03), particularly in the stromal compartment. Conclusions', ' These data, representing PD-L1 and CD8 expression profiles for a BRAF-mutant mm population in the context of outcomes following D+T, showed that clinical benefit was maintained regardless of immune phenotype. The results also suggest that an immune component has an impact on outcomes following targeted therapy. Clinical trial information', ' NCT01597908']",
        "Doc_id":"ASCO_182461-199",
        "Doc_title":" PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.",
        "_version_":1606189013625995264},
      {
        "Meeting_name":" Analysis of PDL1 expression and T cells infiltration in 1014 gastric cancer patients.",
        "Background":"['Background', ' Although immune checkpoint inhibitors have demonstrated promising results in melanoma and lung cancer, their effects on gastrointestinal cancer are still under investigation. Understand the prognostic effect of PDL1 expression, infiltration by CD8+ and CD3+ T cells in gastric cancer (GC) might help the identification of candidate patient who might benefit from immunotherapy. Methods', ' Immunohistochemistry were performed on a tissue microarray including 1,014 GC specimens with PD-L1 antibodies. Immune cell markers CD3 and CD8 were also stained and the quantitative differences were calculated using automated image analysis. Results', ' 37.8% of the cases showed a membranous PD-L1 expression in tumor cells and 74.9% in tumor infiltrating immune cells. GC patients with high level PDL1 expression in tumor cells or in immune cells were both associated with better survival compared with those with negative expression (5-year OS, 61% vs. 48%, P = 0.000, and 55% vs. 45%, P < 0.0001, respectively). As continuous variables, higher CD3+ and CD8+ cell density were associated with patients overall survival and the associations remained as the significant prognostic factors that predict favorable outcomes even after adjusting other unknown confounding factors.(HR', ' 0.974, 95%CI', ' 0.963-0.985, P = 0.000; and HR', ' 0.973, 95%CI', ' 0.960-0.986, P = 0.000 for CD3 and CD8 respectively). We also observed the close relationship between CD3+, CD8+ cell density and PDL1 expression both in tumor cells and in infiltrating immune cells. Conclusions', ' This study indicates that PDL1 expression, and TILs in particular, are important prognostic biomarkers. Patients with higher CD8 and CD3 T cell densities also have higher PD-L1 expression, indicating an adaptive immune resistance mechanism may be occurring. The counterintuitive observation that higher PD-L1 expression associating with better patients outcome highlights the need to assess both PDL1 expression in all tumor compartments and the characterization of the GC immune microenvironment.']",
        "Doc_id":"ASCO_176559-195",
        "Doc_title":" Analysis of PDL1 expression and T cells infiltration in 1014 gastric cancer patients.",
        "_version_":1606189012838514689},
      {
        "Meeting_name":" HDAC6, new role as master regulator of PD-L1 and immune-related pathways",
        "Background":"['Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to modify a variety of other proteins involved in diverse cellular processes unrelated to the chromatin environment, including the modulation of proteins related to cell cycle/apoptosis and immune regulation. In contrast to the well-documented effects of HDAC inhibitors (HDACi) in the control of cell cycle and apoptosis, their role in immunobiology is still not completely understood, and the reported immunological outcomes when using HDACi are heterogeneous. Our group recently reported that the pharmacological or genetic abrogation of a single HDAC, HDAC6, modulates the expression of immuno-regulatory proteins, including PD-L1, PD-L2, MHC class I, B7-H4 and TRAIL-R1. We primarily focused in PD-L1, which is an important negative regulator of T-cell function and often over-expressed in cancer cells. In a mechanistic point of view, we have found that the pharmacological inhibition and genetic abrogation of HDAC6 inactivates the STAT3 pathway, impairs the nuclear translocation and the recruitment of STAT3 to the PD-L1 promoter and subsequently down-regulates the expression of PD-L1. Moreover, the in vivo abrogation of HDAC6 reduces tumor growth in melanoma models, effect that is enhanced in the presence of the immune check-point blocking antibodies anti-PD-1 and anti-CTLA4. These results provide a key pre-clinical rationale and justification to further study isotype selective HDAC6 inhibitors as potential immunomodulatory agents in cancer.']",
        "Doc_id":"AACR_2016-2331",
        "Doc_title":" HDAC6, new role as master regulator of PD-L1 and immune-related pathways",
        "_version_":1606188990194515968},
      {
        "Meeting_name":" Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer",
        "Background":"['Lung cancer remains a major cause of cancer mortality. Malignant lesions are normally endogenously corrected by the immune surveillance system. However, tumors evade this immunity by inducing immunosuppressive microenvironments during cancer progression. It has been thought that there are two critical components of tumors making them capable of maintaining the immunosuppressive microenvironment. One is the inhibition of cytotoxic T lymphocytes (CTL) activity against the tumor through immune checkpoint molecules, such as programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1), which are negative regulators of CTL, and the other is by the induction of tumor infiltrating immune suppressive cells, which can deactivate the CTL. Recent studies demonstrate that multiple cancer types, including melanoma, lung, kidney, bladder, and stomach, respond to immune checkpoint inhibitors, such as PD-L1 and PD-1 with 11-30% response rates and durable responses. However, a substantial number of patients still fail to respond to immunotherapy and the refractory mechanisms are largely unknown. In this study, we focus on KRas-driven lung cancers, as there are no clinically effective targeted drugs available for treating this type of lung cancer. We demonstrate that during the progression of tumors in KRas mutation and p53 knockout-driven lung cancer mouse models; KRasG12D/+;p53-/- (KP), there is a gradual increase in the number of myeloid derived suppressor cells (MDSC) and that the combination of either anti-PD-1 or anti-PD-L1 antibody along with a MEK inhibitor, which targets downstream of KRas signaling, shows anticancer efficacy in these animal models. These combinations, in comparison to either single agent alone, effectively blocks the growth of subcutaneously (s.c.) injected syngeneic mouse lung cancer cells in immune competent transgenic KP mice, significantly increasing the survival rates', ' 37.5% (for anti-PD-1 antibody and MEK inhibitor), 62.5% (for anti-PD-L1 antibody and MEK inhibitor) vs. 0% single agents or control at the end of treatment. We find that the tumors in the control treated group harbor a substantial number of immune cells, including PD-L1 expressing MDSC. The combination treatment with either an anti-PD-1 or anti-PD-L1 antibody along with a MEK inhibitor dramatically modulates the composition and the activity of tumor infiltrated immune cells. Tumors in the combined treated group show a significant decrease in PD-L1 expressing MDSC in comparison with control tumors. Additionally, a combined treatment would block the PD-L1 activity of the infiltrated PD-L1 expressing MDSC in malignant tumors and thus lead to improved survival. These results point to a potential therapeutic opportunity for currently untargetable KRas-driven lung cancers.']",
        "Doc_id":"AACR_2016-2334",
        "Doc_title":" Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer",
        "_version_":1606188979400474624},
      {
        "Meeting_name":" ENCORE 601",
        "Background":"['Background', ' Entinostat is an oral, class I selective histone deacetylase inhibitor shown preclinically to enhance immune checkpoint inhibitor activity by regulation of immune suppressor cells in the tumor microenvironment. ENCORE 601 is designed to evaluate safety and efficacy of ENT in combination with PEMBRO. Phase 1b identified ENT 5 mg PO weekly and PEMBRO 200 mg IV every 3 weeks as the recommended Phase 2 dose for further investigation. Methods', ' Phase 2 of ENCORE 601 employs a Simon 2-stage design to assess activity across 3 cohorts', ' 1) NSCLC not previously treated with a PD-1/L1 blocking antibody, 2&3) NSCLC & melanoma previously progressing on or after a PD-1/L1 blocking antibody. Patients were enrolled irrespective of PD-L1 expression levels. The primary endpoint is ORR as assessed by irRECIST. Results of the first stage of Cohort 3 are reported. Criteria for advancing to Stage 2 are 2 responses out of 13 evaluable patients. Results', ' Stage 1 enrollment has been completed (n = 13). All patients received a prior PD-1 inhibitor; in addition, 7 patients received prior ipilimumab and 2 patients received a prior BRAF inhibitor. 9 patients are still on treatment; 4 patients have discontinued due to progression. To date, 1 confirmed and 1 unconfirmed objective response have been observed. The confirmed response (PR) was in a patient who was previously treated with ipilimumab/nivolumab for 6 months (best response of SD with subsequent progression on therapy). Treatment-related AEs occurred in 5 patients (most common being nausea and fatigue occurring in 2 patients); one patient experienced Gr3/4 events (fatigue and rash). Blood samples and pre-treatment biopsies were obtained in all patients along with paired post-treatment biopsies in 8 patients. Evaluation of PD-L1 expression, gene expression, myeloid and lymphoid compartments in blood and tumor samples is in progress. Of note, the patient with a confirmed PR converted from a PD-L1 negative, non-inflamed gene signature to PD-L1 positive, inflamed after 2 weeks of treatment. Conclusions', ' ENT combined with PEMBRO demonstrates acceptable safety and encouraging preliminary activity in melanoma patients refractory to checkpoint inhibitors. Clinical trial information', ' NCT02437136']",
        "Doc_id":"ASCO_184166-199",
        "Doc_title":" ENCORE 601",
        "_version_":1606189027166257152},
      {
        "Meeting_name":" Immune microenvironment in brain metastases of breast cancer.",
        "Background":"['Background', ' In patients with brain metastasis (BM) of melanoma or lung cancer, significant activity of immune checkpoint inhibitors has been reported. However, details of the immune microenvironment in BM has not been unveiled. In this study, we used immunohistochemistry (IHC) to compare primary breast tumors and BM tumor samples with respect to tumor infiltrating lymphocytes (TILs) and tumor characteristics related to the immune system. Methods', ' We retrospectively identified 107 patients with breast cancer, diagnosed with BM, who had undergone surgery between 2001 and 2012 at 8 institutions. We collected 191 samples which included both BM samples alone and pair-matched samples (primary and BM). Hematoxylin and eosin (H&E) stained slides were evaluated for stromal TILs in 10% increments (01%, > 1< 10%, 10%100%). IHC was performed using the following primary antibodies', ' CD4, CD8, Foxp3, PD-L1, PD-L2 and HLA class I. The cells positive for each antibody signal were counted automatically using ImageJ (NIH). The expression of PD-L1, PD-L2, and HLA on the tumor cells was scored as 0 (negative), 1 (weak or focal), or 2 (strong). Results', ' The median category of TILs of BM tumors was > 1< 10% (range', ' 130%). Forty-six pair-matched samples were analyzed and the percentage of TILs in the primary breast tumor was significantly higher than that in BM samples (paired t-test, P < 0.01). The number of CD4/CD8/Foxp3 positive cells in primary breast tumor was also significantly higher than in BM samples (paired t-test, P < 0.05 for all categories). The negative/positive conversion occurred with the expression of HLA/PD-L2 on tumor cells (paired t-test, P = 0.03/0.06, respectively). No significant difference was observed in the overall survival (OS) of patients, from initial BM, based on high or low TILs (log-rank test, P = 0.131). However, triple negative breast cancer patients with low TILs had significantly shorter OS compared with patients with high TILs (log-rank test, P = 0.04). Conclusions', ' We demonstrated that TILs in BM tumors was significantly lower as compared to primary breast tumors. The expression of immune related molecules on tumor cells was converted in BM tumors.']",
        "Doc_id":"ASCO_181350-199",
        "Doc_title":" Immune microenvironment in brain metastases of breast cancer.",
        "_version_":1606189021933862912},
      {
        "Meeting_name":" Tumor mutational load in gynecological and breast cancer.",
        "Background":"['Background', ' Lack of test standardization and conflicting results on PD1 and PD-L1 immunohistochemistry (IHC) assays challenge their use as predictive biomarkers for checkpoint inhibitors. High tumor mutational load (TML) has been linked to therapeutic response with immune checkpoint inhibition in melanoma, lung and colorectal cancer. Herein, we explore association of TML and PD1/PD-L1 expression in gynecological (GC) and breast cancer (BC). As secondary aim we explore the association of TML with BRCA1/2 mutations. Methods', ' De-identified data from molecular profiling on GC and BC tumors from the CARIS Life Sciences database was analyzed after obtaining IRB approval. TML was defined as the total number of nonsynonymous, somatic mutations per Mb sequenced with a 592-gene panel. PD-1 IHC was tested on Tumor Infiltrating Lymphocytes (TIL) with the cutoff of 1/HPF; PD-L1 expression was measured on tumor cells with the cutoff of 2+, 5%. Biomarker association was tested with ANOVA test (SPSS v23, IBM). Results', ' As shown in table, cervical (CC) and endometrial cancers (EC) had the highest TML and squamous CC and triple negative BC (TNBC) tumors with highest PD-L1. In EC, MSI-H was associated with higher TML when compared to MSS (20.1 vs. 6.1, p<0.001); 4 POLE-mutated tumors all carried TML (36-678) higher than mean (11.5). TML was not associated with PD1 or PDL1 positivity in any of the diseases. BRCA1/2 mutations were associated with higher mean TML in ovarian cancer (OC) (6.8 vs. 5.4 in wild type, p<0.001) but not in BC (6.3 vs. 6.8 in wild type, p=0.48). Conclusions', ' In this sample of patients who underwent molecular profiling, there was no association between TML and PD1 or PD-L1 expression. Association between BRCA1/2 tumor mutations and TML in OC is worth exploring. High TML in CC and EC support the development of immunotherapy for these diseases. NTMLPD-L1 %PD-1 %MeanS.E.OCAll6745.70.16.362serous4385.40.15.665CCAll*827.680.723.561Squamous468.50.934.7838Adeno286.61.23.778EC35611.52.05.272Uterine SarcomaAll615.00.3250Leiomyosarcoma295.40.53.8542BCAll6906.30.15.447HR+ Her2-3545.90.22.538HR+ Her2+386.40.7035HR-Her2+387.71.03.256TNBC2606.70.310.761*One case of POLE-mutated CC was excluded (TML 530)']",
        "Doc_id":"ASCO_178375-194",
        "Doc_title":" Tumor mutational load in gynecological and breast cancer.",
        "_version_":1606188989707976704},
      {
        "Meeting_name":" Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies.",
        "Background":"['Adenosine signaling via A2A receptor (A2AR) on immune cells suppresses anti-tumor immunity and limits the efficacy of immunotherapy, chemotherapy, CAR-T, and vaccines. CPI-444 is a potent and selective oral A2AR antagonist. Daily treatment of mice with CPI-444 led to dose-dependent inhibition of tumor growth in multiple syngeneic tumor models. Combining CPI-444 with anti-PD-L1 treatment synergistically eliminated tumors in up to 90% of treated mice, including restoration of immune responses in models that are poorly responsive to anti-PD-1 or anti-PD-L1 monotherapy. We have initiated a Phase 1/1b clinical trial to examine safety, tolerability, biomarkers, and preliminary efficacy of CPI-444 as a single agent and in combination with the anti-PD-L1 antibody, atezolizumab, in patients with non-small cell lung, melanoma, renal, triple negative breast, and other (bladder, prostate, head and neck, colorectal) tumors. Step 1 of the trial focused on determining the optimal dose and schedule for CPI-444; Step 2 is currently evaluating the efficacy of optimal CPI-444 dosing alone and with atezolizumab. In 48 patients treated in Step 1, CPI-444 was well tolerated with 1 Grade 3 or 4 treatment related adverse events. Preliminary evidence of clinical activity was observed in patients treated with single agent CPI-444, including patients who previously failed anti-PD-1 therapy. A pCREB-based pharmacodyamic assay showed that 100 mg, BID dose of CPI-444 resulted in a complete, sustained inhibition of A2AR on circulating immune cells. CPI-444 treatment alone or in combination with atezolizumab resulted in increased frequency of circulating CD8+PD-1+ cells and memory/effector subsets of CD4+ and CD8+ T cells. Substantial changes in TCR repertoire (Morisita Index <0.9) were observed in both anti-PD-1 native and refractory patients and correlated to patient responses. CD73 expression, CD8+ infiltration, TREG distribution, and gene expression signatures are currently being evaluated in serial tumor biopsy specimens and will be presented. In total, this shows that CPI-444 is well tolerated in cancer patients, exhibits functional inhibition of adenosine signaling, and treatment is associated with activation of anti-tumor immunity and clinical activity.']",
        "Doc_id":"AACR_2017-5593",
        "Doc_title":" Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies.",
        "_version_":1606189041870438401},
      {
        "Meeting_name":" Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types.",
        "Background":"['With the advent of immune therapies including inhibition of the PD-1/PD-L1 axis there is an urgent need to identify cancer patients that benefit from these therapies and to overcome mechanisms of resistance. Here, we analyzed the impact of tumor genetics on the composition of tumor microenvironment across 21 solid cancer types from the TCGA project. Using specific mRNA markers of 10 cell populations (MCPcounter), we estimated the content of T cells, CD8+ T cells, cytotoxic lymphocytes, B lineage cells, NK cells, monocytic lineage cells, myeloid dendritic cells, neutrophils, fibroblasts and endothelial cells in tumor tissues. Immune cell compositions were correlated with mutational load, the activity of 27 mutational signatures (MutSigs) and PD-L1 mRNA expression. Correlation strength was assessed using Spearmans rho statistics. Multiple testing was addressed using the Benjamini-Hochberg method and FDR control at 5%. MutSig 1 (clock-like, age-related) showed significant positive correlations with immune cell infiltrations in low-grade gliomas, negative correlations in breast cancer, melanoma, stomach cancer, lung and prostate adenocarcinoma, but no significant correlations in the remaining 15 cancer types. Of the two APOBEC-related signatures, MutSig 2 showed positive significant correlations with immune cell infiltrates in cervical cancer, bladder cancer, lung adenocarcinoma, head and neck cancer and thyroid cancer, MutSig 13 in breast and cervical cancer. In particular, correlation of MutSig 2 with cytotoxic lymphocytes was significant in cervical cancer, bladder cancer and lung adenocarcinoma (R = 0.29, R= 0.17 and R = 0.17), the corresponding correlation of MutSig 13 in breast cancer (R = 0.17). MutSig 4 (tobacco smoke-related) showed a positive significant correlation with CD8+ T cells and NK cells in lung adenocarcinoma (R = 0.15 and R = 0.14). In contrast, correlation of MutSig 4 with immune cell infiltrates was non-significant or negative in head and neck cancer. In colorectal cancer, MutSig 6 (defective mismatch repair) showed significant positive correlations with NK cells, cytotoxic lymphocytes, monocytic lineage cells and neutrophils infiltration (R = 0.45, R = 0.37, R = 0.23 and R = 0.19). PD-L1 mRNA expression and immune cell infiltrates correlated positively in all 21 cancer types. In particular, correlation with monocytic lineage cells was positive and significant in all cancer types and strong (R > 0.50) in 12 cancer types. Correlation with T cells was positive and significant in 18 cancer types and strong in 10 cancer types. In summary, pan-cancer analysis of DNA and RNAseq data showed that specific mutational signatures contribute to cancer cell immunogenicity, while the ubiquitous clock-like mutational process did not positively correlate with immune cell infiltrates in 20 of 21 cancer types. Moreover, PD-L1 mRNA expression strongly correlated with infiltrates of immune cells in the majority of cancer types.']",
        "Doc_id":"AACR_2017-3709",
        "Doc_title":" Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types.",
        "_version_":1606188979933151232},
      {
        "Meeting_name":" Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine",
        "Background":"['Immune checkpoint(s) blockade is becoming the therapeutic mainstay in melanoma and lung cancer. Based on these important clinical achievements, immunotherapy with immunomodulating monoclonal antibodies (mAb) is being explored as a new therapeutic modality in most human malignancies, either alone or in combination with other immunomodulating agents. We have provided extensive evidence that the second generation DNA hypomethylating agent (DHA), guadecitabine (SGI-110), plays a promising role in potentiating the immunogenicity and the immune recognition of human malignancies through the up-regulation of the expression of different immune molecules on cancer cells. These findings led us to hypothesize that DHA could represent ideal partners for immune checkpoint(s) blocking agents to improve their therapeutic efficacy. Here, we studied the expression of programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and 2 (PD-L2), and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) in peripheral blood mononuclear cells of acute myeloid leukemia (AML) patients (N = 23), enrolled in a phase 1-2 study with guadecitabine. Patients included in this preliminary analysis were selected based on their responsiveness to therapy. Quantitative RT-PCR analyses showed a constitutive expression (gene/-actin molecules >7.5E-05) of PD1, PD-L1, PD-L2 and CTLA-4 in 82.6%, 100%, 47.8% and 8.7% patients, respectively. Guadecitabine therapy up-regulated (2 fold) the expression of PD1, PD-L1, PD-L2 and CTLA-4 in 57.9%, 56.5%, 18.2% and 0% patients, respectively, at any of the time-points investigated during treatment. De novo expression of PD1, PD-L2 and CTLA-4 was observed in 100%, 41.6% and 38.1% of the immune checkpoint(s)-negative patients, respectively.Though preliminary, these results further support the strong link between epigenetics/DNA methylation and immune response, in cancer patients, and strengthen the therapeutic potential of epigenetic immunomodulation, with consolidated and emerging immune checkpoint(s) blocking mAb.']",
        "Doc_id":"AACR_2016-2325",
        "Doc_title":" Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine",
        "_version_":1606188980741603328},
      {
        "Meeting_name":" Biomarker-driven indication selection in JTX-2011 ICONIC clinical trial.",
        "Background":"['Background', ' ICOS (Inducible T cell CO-Stimulator) is a co-stimulatory molecule expressed primarily on T lymphocytes. Clinical and preclinical data suggest that ICOS mediates anti-CTLA-4 driven anti-tumor responses. JTX-2011 is an ICOS agonist antibody in clinical development in advanced solid tumors (ICONIC trial). JTX-2011 is designed to generate an anti-tumor immune response via stimulation of T effector cells and preferential reduction of intra-tumoral T regulatory cells. Single agent preclinical efficacy correlates with the percentage of ICOS-expressing T cells within the tumor. We report indication selection and patient enrichment strategy for ICONIC using in silico and IHC analysis and assessment of potential predictive biomarkers for JTX-2011 using ex vivo tumor histoculture. Methods', ' Integrated analysis was performed from the TCGA for ICOS expression in histologic and molecularly defined tumors and immune cell signatures. ICOS expression was analyzed by IHC in a subset of indications based on in silico analysis. ICOS expression on intra-tumoral Tregs and PD-L1 were analyzed in a cohort of 126 head and neck squamous cell carcinomas (HNSCC). Ex vivo histoculture assays of human HNSCC was treated with JTX-2011 and assessed for IFNg gene signature induction. Results', ' ICOS mRNA expression was analyzed in ~10,000 solid tumors samples across ~30 indications. ICOS expression in key indications was confirmed using IHC. Based on frequency of high ICOS expression, non-small cell lung cancer, HNSCC, triple negative breast carcinoma, gastric cancer, and melanoma were selected as indications for ICONIC. Results were confirmed in clinical samples using multiplex immunofluorescence and ICOS IHC. A wide range of ICOS expression was observed suggesting that identification of an ICOS high group may enrich for patients likely to benefit from ICOS agonist therapy. In ex vivo histoculture assays of human HNSCC tumors treated with JTX-2011, ICOS IHC and ICOS RNA gene signatures correlated to response endpoints. Comparison of ICOS and PDL1 expression identified subsets of tumors in multiple indications with high ICOS but low PDL1 expression. Conclusions', ' These data support prioritization of specific tumor types the ICONIC trial.']",
        "Doc_id":"ASCO_192215-199",
        "Doc_title":" Biomarker-driven indication selection in JTX-2011 ICONIC clinical trial.",
        "_version_":1606189014846537728},
      {
        "Meeting_name":" Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma",
        "Background":"['Background', ' Predictive biomarkers for response and resistance to immune checkpoint blockade targeting programmed death 1 (PD-1) are incompletely characterized, and the utility of anti-PD-1 therapy for uterine leiomyosarcoma (ULMS) is unknown. Methods', ' A 49 yo woman with ULMS developed rapidly progressive metastatic disease 4 months after R1-resection of the primary tumor and was enrolled on a phase 1b study of pembrolizumab (10 mg/kg every 2 wks) (KEYNOTE-028). Tumor regression at multiple metastatic sites occurred within 2 months. A single pre-existing metastasis increased in size and was resected at 9 months. IHC, whole exome/transcriptome sequencing, and neoantigen analysis was performed on primary pretreatment (preRx) and treatment-resistant tumors (postRx). Results', ' Responsive tumor sites revealed complete pathologic response at time of surgery. Progressive tumor demonstrated viable ULMS. IHC showed tumor cells negative for PD-L1 and positive for PD-L2 both preRx and postRx. Degree of PD-1+ lymphocyte infiltration decreased significantly postRx compared to preRx. PreRx harbored exomic focal MYC amplification, TP53 nonsense mutation, and heterozygous PTEN deletion. PostRx maintained these genomic alterations and acquired a loss-of-function mutation in PTEN that resulted in biallelic PTEN inactivation. PreRx tumor expressed tumor-specific neoantigens (TSNs) that were immunogenic to patient-derived peripheral blood mononuclear cells; expression of TSNs decreased postRx. Conclusions', ' This patient exhibited complete pathologic response to pembrolizumab at all but one metastatic ULMS site. Genomic analysis of the resistant tumor revealed acquired bialllelic PTEN loss - recently implicated in resistance to PD-1 inhibition in melanoma and glioblastoma  reduced infiltration of PD-1+ lymphocytes, and diminished expression of neoantigens. To our knowledge, this is the first report of exceptional response to PD-1 inhibition in ULMS, and highlights biallelic PTEN loss and neoantigen downregulation as potential mechanisms of acquired resistance to immune checkpoint blockade across cancer types.']",
        "Doc_id":"ASCO_166429-176",
        "Doc_title":" Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma",
        "_version_":1606189008174448640},
      {
        "Meeting_name":" Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.",
        "Background":"['Background', ' A phase 1 trial to assess the safety and immunological activity of the combination of varlilumab (V) and nivolumab (N), and recommend a dose of V for the phase 2 study was conducted. Methods', ' The study was performed using the approved dose of N (3 mg/kg Q2W) and escalating doses of V (0.1, 1, or 10 mg/kg Q2W) in anti-PD-(L)1 nave patients with advanced cancer. Results', ' A total of 36 patients (21 CRC, 8 ovarian [OVA], 4 melanoma and 3 SCCHN) were enrolled. Toxicity was consistent with the safety profile of each agent individually; no unexpected toxicities were seen with the combination. No MTD was identified. An OVA cancer patient in the 10 mg/kg cohort had a DLT', ' hepatitis (G4) and acute kidney injury (G3). A CRC patient in the 10 mg/kg cohort had a drug-related SAE of mixed motor sensory neuropathy (G2) and a CRC patient in the 1 mg/kg cohort had rash (G3). No additional drug related SAEs or DLTs were reported. The majority of tumors were PD-L1 negative (24/27) by IHC at baseline. For patients with post treatment biopsies, PD-L1 expression was observed in 43.5% (10/23) and correlated with increases in CD8 T cell infiltration, consistent with the generation of anti-tumor immunity. Other treatment related biomarker changes included transient increases in serum chemokine levels, and a prominent decrease in circulating Tregs. Biomarker analysis did not clearly differentiate between dose levels, or delineate an optimal V dose. Three patients had objective PR by RECIST [CRC MSI-low (1 mg/kg V), SCCHN (10 mg/kg V) and OVA (10 mg/kg V, uPR)]. The response in the CRC patient is ongoing with a 94% decrease in target lesion diameter and a PFS of 19+ months. There were also 11 patients with SD. Phase 2 cohorts are ongoing in RCC, SCCHN, OVA, CRC and GBM. The Phase 2 portion includes exploration of different dose/regimens of V, including high and low exposure, to better characterize the optimal dosing strategy for V, in combination with a fixed dose of N (240 mg Q2W). Conclusions', ' The combination of V and N was well tolerated, associated with strong biological signals, and has evidence of clinical activity in subsets of patients with tumor types that are typically resistant to PD-1 inhibitor monotherapy. Clinical trial information', ' NCT02335918']",
        "Doc_id":"ASCO_185799-199",
        "Doc_title":" Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.",
        "_version_":1606188998084001793},
      {
        "Meeting_name":" Natural killer cells as a predictive biomarker for response to anti-PD-1 therapy in patients with advanced solid tumors.",
        "Background":"['Background', ' Assessment of PD-L1 expression in tumor biopsy has been widely used for predicting anti-PD-1 therapy. Several factors, including tumor heterogeneity, false negative staining and unavailability of biopsy samples limit the application. Natural killer (NK) cells exert cytotoxicity against cancer cells. Therefore, we explored using NK cells percentage in peripheral blood (PB) as a biomarker to identify pts who are more likely to benefit from anti-PD-1 therapy. Methods', ' Pts treated with anti-PD-1 antibody (JS001) 1 mg/kg, 3mg/kg or 10mg/kg every 2 weeks in a Phase I clinical trial (ClinicalTrials.gov Identifier', ' NCT02836795) had PB collected at baseline and at time of radiographic evaluation performed every 8 wks. Disease status (shrinking stable disease, growing stable disease, partial response, complete response, or progressive disease) was characterized using RECIST v1.1 and immune-related response criteria. Frequencies of NK cells (CD3-CD16+CD56+) were measured by flow cytometry. Results', ' Thirty-six patients were enrolled in this trial, including 22 melanoma, 9 urothelial carcinoma and 5 renal cell carcinoma. As of 1/27/2017, median treatment duration', ' 3.92 months. Radiographic tumor evaluation has been performed in 32 pts', ' 1/32 CR, 6/32 PR, 6/ 32 shrinking SD, 4/32 growing SD and 15/32 PD. Pts with high NK cells at baseline observed 60% (6/10) Clinical Benefit Rate (CR/PR/ shrinking SD) versus 40% (13/32) in overall pts. Patients with clinical benefit had higher frequency of NK cells at baseline compared to pts with radiographic growing SD and PD (mean 24.3% vs. 17.9%, P = 0.076). Furthermore, pts with NK cell level consistently above UN or increasing above UN during treatment are more likely to get clinical benefit than those under UN (7/10 vs 3/22, P = 0.013). Conclusions', ' Baseline high NK cells frequency may predict a favorable response to anti-PD-1 therapy, which provides a non-invasive way to monitor response to PD-1 blockade. These results are being validated in a phase II trial. Clinical trial information', ' NCT02836795']",
        "Doc_id":"ASCO_189658-199",
        "Doc_title":" Natural killer cells as a predictive biomarker for response to anti-PD-1 therapy in patients with advanced solid tumors.",
        "_version_":1606189022535745536},
      {
        "Meeting_name":" Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).",
        "Background":"['Background', '  Pembrolizumab, an antiPD-1 monoclonal antibody, has shown antitumor activity in advanced gastric cancers. Hypothesis testing of 4 prespecified multigene immune expression signatures enriched for T-cell mediated interferon signaling and antigen presentation genes was used to evaluate associations with clinical outcomes in patients with gastric cancer enrolled in KEYNOTE-012, a multicohort, phase 1 study of pembrolizumab in patients with PD-L1+tumors.  Methods', '  33 of 39 pembrolizumab-treated advanced gastric cancer patients had RNA expression profiling data of sufficient quality. RNA was extracted from formalin-fixed, paraffin-embedded samples and analyzed using the NanoStringnCounter system. Hypothesis testing was conducted on 4 prespecified signatures (Interferon-gamma,TCR-signaling,Expanded-immune, and Denovo) that were constructed based on analyses in patients with melanoma and prior to linking any NanoString data to clinical outcome data.  Results', '  In the patients with NanoString data, ORR was 30%. For ORR, all 4 signatures showed a P value <0.10 (Table). For PFS, all signatures achieved P< 0.05. All signatures showed a general pattern such that pts with very low signature scores did not respond. ROC analyses suggest that cutoffs with high sensitivity and a resultant high negative predictive value (NPV) can readily be achieved. The cutoff associated with the Youden Index of the ROC curve for the Interferon-gamma signature yielded a positive predictive value (PPV) of 45% with a NPV at 92%.  Conclusions', '  Immune response signatures were associated with clinical benefit from antiPD-1 therapy with pembrolizumab in patients with advanced gastric cancer enrolled in KEYNOTE-012.      Clinical trial information', ' NCT01848834SignatureNominal One-Sided PaORRN = 33PFSN = 33IFN (6 gene)0.0770.032TCR Signaling (13 gene)0.0340.024Expanded Immune (18 gene)0.0620.049Denovo (33 gene)0.0680.037aFrom logistic or Cox regression for ORR and PFS, respectively.']",
        "Doc_id":"ASCO_152032-156",
        "Doc_title":" Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).",
        "_version_":1606189032946008064},
      {
        "Meeting_name":" Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.",
        "Background":"['Background', '  Nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, and ipilimumab, a fully human IgG1 cytotoxic T-lymphocyte antigen-4 receptor (CTLA-4) blocking antibody, have shown antitumor activity and durable responses in patients (pts) with solid tumors including melanoma, renal cell cancer and non-small cell lung cancer. Preclinical and clinical data indicate that combined PD-1 and CTLA-4 blockade may improve antitumor activity. We hypothesize that nivolumab alone or combined with ipilimumab may have activity in additional solid tumor types. We describe a phase I/II signal detection, open-label study to analyze the safety and efficacy of these agents in locally advanced or metastatic triple-negative breast, small-cell lung, gastric or pancreatic cancerareas of significant unmet medical need.  Methods', '  The primary and secondary objectives of this study are objective response (OR) rate and safety, respectively. Exploratory objectives include progression-free survival, overall survival, immunogenicity, pt-reported global health outcomes, and analysis of pharmacodynamic activity of nivolumab alone or combined with ipilimumab in peripheral blood and tumor tissue. Additionally, evaluation of putative biomarkers such as PD-1 ligand (PD-L1) expression will be performed. The study uses a modified Simon 2-stage design. In stage 1, 36 pts for each tumor type will be assigned 1', '1 to treatment with either nivolumab 3 mg/kg IV Q2W (arm N), or nivolumab 1 mg/kg + ipilimumab 3 mg/kg IV Q3W for 4 doses then nivolumab 3 mg/kg IV Q2W (arm N+I), until progression or toxicity. Responses will be assessed using RECIST criteria at wks 6, 12, 18, 24 and then Q12W. Treatment arms will proceed independently into stage 2 if 2 pts in a given arm for each tumor type have an OR. In stage 2, an additional 22 pts per tumor type will be assigned to each arm (N or N+I) and receive the stage 1 dosing regimen. Key eligibility criteria include ECOG status 1, available fresh or archival tumor tissue, measurable disease by CT or MRI (RECIST 1.1), and adequate bone marrow, liver and renal function. Clinical trial information', ' NCT01928394.']",
        "Doc_id":"ASCO_125706-144",
        "Doc_title":" Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.",
        "_version_":1606189010223366144}]
  }}
